JPRN-UMIN000005692已完成未知
I-131 therapy for thyroid cancer with recombinant human thyroid-stimulating hormone (Thyrogen) - I-131 therapy for thyroid cancer with recombinant human thyroid-stimulating hormone
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) pregnant female and feeding female 2) a patient with disturbed consciousness 3) expected life interval less than 1 month 4) risks for the central nerve system during treatment 5) when medical staff determine that treatment can not be properly carried out
研究者
相似试验
已完成
不适用
I-131 therapy for metastatic thyroid cancer with recombinant human thyroid-stimulating hormone (Thyrogen)Thyroid cancerJPRN-UMIN000013970Asahikawa Medical University10
撤回
2 期
Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid CancerThyroidCancerNCT01396733Asan Medical Center
进行中（未招募）
不适用
Study for metastatic thyroid cancer using 124i and [18F] FDG PET / CT in patients with elevated values of Tg and / or AbTg with negative ultrasonography of the neck, previously treated with thyroidectomy and radioiodine therapy. - I124Only patiensMedDRA version: 14.1Level: SOCClassification code 10022891Term: InvestigationsSystem Organ Class: 10022891 - InvestigationsEUCTR2010-023831-40-ITFONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
撤回
不适用
Fast-track thyroidectomy and I-131 radioiodine ablation therapy in patients with differentiated thyroid cancer.1004373910014713Thyroid cancerNL-OMON38352niversitair Medisch Centrum Utrecht70
进行中（未招募）
1 期
Personalized therapy of metastatic thyroid cancer: biological characterization and optimization with 124I PET dosimetrymetastatic thyroid cancerMedDRA version: 20.0Level: PTClassification code 10076603Term: Poorly differentiated thyroid carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-002548-21-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI50